Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Non-Current AssetsPayablesPrepaid AssetsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fennec Pharmaceuticals (FENC) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for Fennec Pharmaceuticals (FENC) over the last 15 years, with Q3 2025 value amounting to $49.3 million.

  • Fennec Pharmaceuticals' Liabilities and Shareholders Equity fell 1639.48% to $49.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $185.5 million, marking a year-over-year decrease of 1496.89%. This contributed to the annual value of $44.9 million for FY2024, which is 6730.94% up from last year.
  • According to the latest figures from Q3 2025, Fennec Pharmaceuticals' Liabilities and Shareholders Equity is $49.3 million, which was down 1639.48% from $44.9 million recorded in Q2 2025.
  • In the past 5 years, Fennec Pharmaceuticals' Liabilities and Shareholders Equity ranged from a high of $69.2 million in Q1 2024 and a low of $15.6 million during Q2 2022
  • For the 5-year period, Fennec Pharmaceuticals' Liabilities and Shareholders Equity averaged around $35.5 million, with its median value being $28.0 million (2021).
  • Per our database at Business Quant, Fennec Pharmaceuticals' Liabilities and Shareholders Equity crashed by 4462.74% in 2022 and then surged by 22495.24% in 2024.
  • Fennec Pharmaceuticals' Liabilities and Shareholders Equity (Quarter) stood at $26.0 million in 2021, then increased by 3.56% to $26.9 million in 2022, then fell by 0.28% to $26.9 million in 2023, then soared by 67.31% to $44.9 million in 2024, then grew by 9.6% to $49.3 million in 2025.
  • Its Liabilities and Shareholders Equity was $49.3 million in Q3 2025, compared to $44.9 million in Q2 2025 and $46.4 million in Q1 2025.